Jasper Therapeutics, Inc. (JSPR) Bundle
Understanding Jasper Therapeutics, Inc. (JSPR) Revenue Streams
Understanding Jasper Therapeutics, Inc. Revenue Streams
As of September 30, 2024, Jasper Therapeutics, Inc. has not generated any revenue from product sales. The company's current financial activities primarily involve research and development expenditures related to its product candidates.
Breakdown of Primary Revenue Sources
Currently, the company does not have any established revenue sources from commercial product sales. Revenue generation is contingent upon successful development and regulatory approval of its product candidates. The anticipated revenue streams will emerge from future product sales, once the company receives the necessary approvals.
Year-over-Year Revenue Growth Rate
Since the company has not generated revenue from product sales, there is no year-over-year revenue growth rate to report. The focus remains on advancing product candidates through clinical trials.
Contribution of Different Business Segments to Overall Revenue
As of now, there are no specific business segments contributing to revenue, as the company is primarily engaged in research and development activities without any approved products on the market.
Analysis of Significant Changes in Revenue Streams
Given the absence of revenue streams, there are no significant changes to report. The company's financial health is currently characterized by net losses and the need for ongoing capital to support its operational and developmental activities.
| Period | Net Loss (in thousands) | Cash and Cash Equivalents (in thousands) | Accumulated Deficit (in thousands) |
|---|---|---|---|
| September 30, 2024 | $46,948 | $92,502 | $216,548 |
| September 30, 2023 | $47,884 | $86,887 | $169,600 |
As of September 30, 2024, the company incurred a net loss of $46.9 million, with an accumulated deficit of $216.5 million. The cash and cash equivalents stood at $92.5 million, highlighting the company’s need for continued funding as it works toward obtaining regulatory approvals and advancing its product pipeline.
A Deep Dive into Jasper Therapeutics, Inc. (JSPR) Profitability
Profitability Metrics
In assessing the financial health of the company, it is essential to analyze key profitability metrics, including gross profit, operating profit, and net profit margins. The following table summarizes the operational results for the nine months ended September 30, 2024 and 2023:
| Metric | Nine Months Ended September 30, 2024 | Nine Months Ended September 30, 2023 | Change ($) | Change (%) |
|---|---|---|---|---|
| Operating Expenses | $50,954,000 | $51,136,000 | $(182,000) | (0.4%) |
| Loss from Operations | $(50,954,000) | $(51,136,000) | $182,000 | (0.4%) |
| Net Loss | $(46,948,000) | $(47,884,000) | $936,000 | (2%) |
The gross profit margin is currently not applicable as the company has not generated revenue from product sales. The operating loss margin reflects the company's expenses relative to its operational scale, showing a slight improvement in loss from operations year-over-year.
In terms of trends, the net loss for the nine months ended September 30, 2024, was $46.9 million, compared to $47.9 million for the same period in 2023, indicating a 2% decrease in losses. Operating expenses remained relatively stable, with a slight decrease of 0.4% from the previous year.
When comparing profitability ratios with industry averages, the company remains in a challenging position as it has yet to achieve revenue generation. The industry average for biopharmaceutical companies typically sees net profit margins ranging from 10% to 20% once operational. However, this company is currently focused on research and development, which limits its ability to generate profits.
Operational efficiency is also a critical factor in profitability analysis. The company reported total operating expenses of $50.9 million for the nine months ended September 30, 2024. Research and development expenses accounted for $36.0 million, while general and administrative expenses totaled $14.9 million. The following table outlines the breakdown of these expenses:
| Category | Nine Months Ended September 30, 2024 | Nine Months Ended September 30, 2023 | Change ($) | Change (%) |
|---|---|---|---|---|
| Research and Development | $36,049,000 | $37,950,000 | $(1,901,000) | (5%) |
| General and Administrative | $14,905,000 | $13,186,000 | $1,719,000 | 13% |
| Total Operating Expenses | $50,954,000 | $51,136,000 | $(182,000) | (0.4%) |
The overall decrease in research and development expenses by 5% indicates improved cost management, while the increase in general and administrative expenses by 13% reflects rising operational costs associated with scaling up the business. The company's ability to manage these operational costs will be crucial as it seeks to transition toward profitability in the future.
Debt vs. Equity: How Jasper Therapeutics, Inc. (JSPR) Finances Its Growth
Debt vs. Equity: How Jasper Therapeutics, Inc. Finances Its Growth
As of September 30, 2024, Jasper Therapeutics, Inc. reported total liabilities of $15.7 million with current liabilities amounting to $12.5 million. This includes accounts payable of $3.1 million and accrued expenses of $8.3 million.
The company has no long-term debt reported, which positions it favorably in terms of financial flexibility. The absence of long-term obligations allows the company to focus on equity financing to support its growth initiatives.
As of September 30, 2024, the debt-to-equity ratio stands at 0.19, indicating a conservative approach to leveraging compared to industry averages, which typically range between 0.5 and 1.5 for biotech firms.
| Debt Type | Amount (in millions) | Notes |
|---|---|---|
| Current Liabilities | 12.5 | Includes accounts payable and accrued expenses |
| Long-term Debt | 0.0 | No long-term debt reported |
| Total Liabilities | 15.7 | Overall liabilities as of September 30, 2024 |
| Debt-to-Equity Ratio | 0.19 | Indicates low reliance on debt financing |
In 2024, the company successfully raised $47.2 million in net proceeds from an underwritten public offering, demonstrating its ability to access capital markets effectively. This capital raise, combined with existing cash and cash equivalents of $92.5 million, provides a substantial financial buffer for ongoing research and development efforts.
Recent activities include a focus on equity financing over debt. The management plans to continue leveraging public and private equity, strategic alliances, and licensing arrangements to fund operations. Given the high-risk nature of biotech research, this strategy minimizes financial risk associated with debt covenants and interest obligations.
Overall, Jasper Therapeutics, Inc. maintains a balanced approach to financing, with a clear emphasis on equity funding to support its growth trajectory while maintaining minimal debt levels.
Assessing Jasper Therapeutics, Inc. (JSPR) Liquidity
Assessing Jasper Therapeutics, Inc. Liquidity
As of September 30, 2024, Jasper Therapeutics, Inc. reports a strong liquidity position with cash and cash equivalents totaling $92.5 million. This figure positions the company favorably in terms of short-term financial obligations.
Current and Quick Ratios
The current ratio, which measures the ability to cover short-term liabilities with short-term assets, is calculated as follows:
| Current Assets | Current Liabilities | Current Ratio |
|---|---|---|
| $92.5 million | $15.7 million | 5.88 |
The quick ratio, a more stringent measure of liquidity that excludes inventory from current assets, is as follows:
| Quick Assets | Current Liabilities | Quick Ratio |
|---|---|---|
| $92.5 million | $15.7 million | 5.88 |
Analysis of Working Capital Trends
Working capital, defined as current assets minus current liabilities, stands at $76.8 million as of September 30, 2024. This represents a healthy increase from the previous year, indicating effective management of short-term assets and liabilities.
Cash Flow Statements Overview
The cash flow statement for the nine months ended September 30, 2024, reveals the following trends:
| Cash Flow Activities | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Net Cash Used in Operating Activities | ($41,468) | ($35,588) |
| Net Cash Used in Investing Activities | ($456) | ($37) |
| Net Cash Provided by Financing Activities | $47,539 | $101,242 |
| Net Increase in Cash and Cash Equivalents | $5,615 | $65,617 |
Potential Liquidity Concerns or Strengths
Despite a solid liquidity position, Jasper Therapeutics faces potential liquidity concerns due to ongoing net losses and negative cash flows from operations. For the nine months ended September 30, 2024, the company incurred a net loss of $46.9 million, consistent with previous periods. The accumulated deficit as of the same date stands at $216.5 million, indicating the need for continued capital raising efforts to sustain operations.
Management has indicated plans to monitor expenses and may pursue additional funding through public and private equity, debt financing, and strategic alliances to address these liquidity needs.
Is Jasper Therapeutics, Inc. (JSPR) Overvalued or Undervalued?
Valuation Analysis
Is Jasper Therapeutics, Inc. Overvalued or Undervalued?
To assess whether the company is overvalued or undervalued, we will analyze key financial ratios such as the price-to-earnings (P/E), price-to-book (P/B), and enterprise value-to-EBITDA (EV/EBITDA) ratios.
- P/E Ratio: As of September 30, 2024, the company reported a net loss per share of $1.24. Given a stock price around $30.00, the P/E ratio is currently N/A due to negative earnings.
- P/B Ratio: The book value per share was calculated as follows: Total Stockholders' Equity of $83.68 million divided by 15,001,353 shares outstanding gives a book value per share of approximately $5.58. Using a stock price of $30.00, the P/B ratio is 5.37.
- EV/EBITDA Ratio: The enterprise value (EV) is calculated as market capitalization ($30.00 x 15,001,353 = $450.04 million) plus total debt ($15.73 million) minus cash and cash equivalents ($92.50 million), resulting in an EV of about $373.27 million. The EBITDA for the last twelve months was approximately $(50.95 million). Thus, the EV/EBITDA ratio is N/A due to negative EBITDA.
Stock Price Trends
Over the past 12 months, the stock price exhibited significant volatility:
- Lowest price: $4.24
- Highest price: $30.00
- Current price as of November 6, 2024: $30.00
Dividend Yield and Payout Ratios
The company does not currently pay dividends, resulting in a dividend yield of 0% and a payout ratio of 0%.
Analyst Consensus on Stock Valuation
As of the latest reports, the analyst consensus for the stock is:
- Buy: 4 analysts
- Hold: 2 analysts
- Sell: 1 analyst
| Metric | Value |
|---|---|
| P/E Ratio | N/A |
| P/B Ratio | 5.37 |
| EV/EBITDA Ratio | N/A |
| Current Stock Price | $30.00 |
| Lowest Stock Price (12 months) | $4.24 |
| Highest Stock Price (12 months) | $30.00 |
| Dividend Yield | 0% |
| Payout Ratio | 0% |
| Analyst Consensus (Buy/Hold/Sell) | 4/2/1 |
Key Risks Facing Jasper Therapeutics, Inc. (JSPR)
Key Risks Facing Jasper Therapeutics, Inc.
Jasper Therapeutics, Inc. faces several internal and external risks that could impact its financial health and operational viability. These risks include industry competition, regulatory changes, and market conditions that could hinder the company’s growth prospects.
Operational Risks
As of September 30, 2024, the company reported an accumulated deficit of $216.5 million. The net losses were $18.6 million for the three months ended September 30, 2024, and $46.9 million for the nine months ended September 30, 2024, indicating ongoing financial challenges .
Financial Risks
The company has experienced negative cash flows from operations, which were $41.5 million for the nine months ended September 30, 2024, compared to $35.6 million for the same period in 2023 . As of the same date, cash and cash equivalents stood at $92.5 million, but the need for substantial additional funding is critical as the company is not expected to generate revenue from product sales until product candidates receive regulatory approval .
Strategic Risks
The company anticipates needing to raise additional capital through a combination of public and private equity, debt financing, strategic alliances, and licensing arrangements. However, the ability to access capital is uncertain and could significantly affect operations .
Market Risks
Market conditions have shown volatility, with the company's stock price ranging from $4.24 to $27.40 in 2023, and from $6.63 to $30.00 in 2024. Such fluctuations may hinder the company's ability to raise funds at favorable terms.
| Risk Type | Details |
|---|---|
| Operational Risk | Accumulated Deficit: $216.5 million |
| Financial Risk | Net Loss (Q3 2024): $18.6 million |
| Financial Risk | Negative Cash Flows (9M 2024): $41.5 million |
| Market Risk | Stock Price Range (2023): $4.24 - $27.40 |
| Market Risk | Stock Price Range (2024): $6.63 - $30.00 |
In light of these risks, the management is focused on monitoring expenses closely and exploring various funding options to ensure operational continuity .
Future Growth Prospects for Jasper Therapeutics, Inc. (JSPR)
Future Growth Prospects for Jasper Therapeutics, Inc.
Analysis of Key Growth Drivers
The company is focusing on several key growth drivers, including:
- Product Innovations: The company continues to develop its briquilimab monoclonal antibody for various indications, including chronic urticarias, and plans to expand its pipeline with additional mast cell indications.
- Market Expansions: The company has exclusive license agreements for the global commercialization of briquilimab, which positions it well in the therapeutic market.
- Acquisitions: Future acquisitions or in-licensing of targeted therapies are anticipated to enhance the product pipeline.
Future Revenue Growth Projections and Earnings Estimates
As of September 30, 2024, the company reported an accumulated deficit of $216.5 million and projected significant expenses associated with research and development. Future financing will be crucial for sustaining operations and product development.
Revenue growth projections remain uncertain, as the company does not expect to generate revenue from product sales until regulatory approval is achieved. Current net losses are reported at $46.9 million for the nine months ended September 30, 2024.
Strategic Initiatives or Partnerships Driving Future Growth
The company has established exclusive agreements with major players such as Amgen and Stanford University. These partnerships are aimed at enhancing the development and commercialization of its product candidates, particularly briquilimab, which is expected to play a significant role in the future growth trajectory of the company.
Competitive Advantages Positioning the Company for Growth
Key competitive advantages include:
- Strong Research and Development Focus: The company invests heavily in R&D, with expenses of $36.0 million for the nine months ended September 30, 2024.
- Robust Intellectual Property Portfolio: The company is committed to maintaining and expanding its IP rights, which is essential for protecting its innovations.
- Experienced Management Team: The leadership team has a proven track record in the biotechnology sector, enhancing strategic decision-making.
| Financial Metric | As of September 30, 2024 | As of September 30, 2023 |
|---|---|---|
| Cash and Cash Equivalents | $92.5 million | $86.9 million |
| Net Loss | $46.9 million | $47.9 million |
| Total Operating Expenses | $50.9 million | $51.1 million |
| Research and Development Expenses | $36.0 million | $37.9 million |
The company plans to continue leveraging its R&D capabilities while managing operational costs to navigate its path towards future profitability. Strategic partnerships and licensing agreements will further enhance its growth potential in the competitive biotech landscape.
Jasper Therapeutics, Inc. (JSPR) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Jasper Therapeutics, Inc. (JSPR) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Jasper Therapeutics, Inc. (JSPR)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Jasper Therapeutics, Inc. (JSPR)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.